Elevar Therapeutics, Inc. – FDA Inspection, May 20, 2026

Record Details

This FDA Inspection record concerns Elevar Therapeutics, Inc., with an inspection on May 20, 2026, issued by the New Jersey District Office, covering human drugs.

Company: Elevar Therapeutics, Inc.
Inspection Date: May 20, 2026
Product Type: Human Drugs
Office: New Jersey District Office
Person: Michael Serrano (Company Rep)

View Company Profile

ID · e2af1881-6c26-4bf1-8066-a70eb21ed836

Inspection Facts

Inspection number: 1318414
FDA center: Human Drugs
Project area: Bioresearch Monitoring
Outcome: Form 483 issued

FDA Citations

21 CFR 312.56(b)Investigator non-compliance

Full citation text and observation details available on the Dashboard.

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Elevar Therapeutics, Inc.

FDA Inspection

Elevar Therapeutics, Inc.May 20, 2026